The company's preparations for the public availability of COVID-19 vaccinations will focus on supporting its members, including high risk members, who wish to receive a COVID-19 vaccine when it becomes available.
These include members who face language barriers and enrollees facing complex clinical conditions that are further complicated by limited access to the social determinants of health, such as transportation, safe housing and economic stability.
AmeriHealth Caritas' approach to facilitating access to the COVID-19 vaccine reflects its mission.
A community-facing organization with nearly four decades of being embedded in the communities it serves, the company has been nationally recognized for its health equity expertise and its cultural competency in meeting the needs of diverse populations.
AmeriHealth Caritas' collaborative efforts will help its members receive timely, people-centered education about vaccines, including information about when they are available and the appropriate distribution points.
Members of AmeriHealth Caritas' health plans with questions about COVID-19 should contact their plan's Member Services team, found on their Member ID card or on their health plan's website.
AmeriHealth Caritas is one of the nation's leaders in health care solutions for those most in need.
Operating in 13 states and the District of Columbia, AmeriHealth Caritas serves approximately 4.5m Medicaid, Medicare, and Children's Health Insurance Program members through its integrated managed care products, pharmaceutical benefit management and specialty pharmacy services, and behavioral health services.
Headquartered in Philadelphia, AmeriHealth Caritas is a mission-driven organization with more than 37 years of experience serving low-income and chronically ill populations.
Eli Lilly announces Q1 2026 dividend
Amgen announces Q4 2025 dividend
Bavarian Nordic secures new EU contract for up to 8 million smallpox and mpox vaccine doses
Thermo Fisher Scientific to acquire Clario Holdings, expanding clinical data capabilities
Nanoform and Revio Therapeutics partner to develop long-acting hydrogel therapy for glioma
Cumberland Pharmaceuticals adds FDA-approved oral capsule for H. pylori to commercial portfolio
IP Group positions for future royalties following Pfizer's USD7.3bn acquisition of Metsera
AstraZeneca strikes landmark drug pricing deal with US Government